Endometrial Cancer

Patients with advanced or metastatic endometrial cancer experienced a significant non-progression rate following treatment with olaparib, metronomic cyclophosphamide, and metformin.

Although patients with endometrial cancer who had histologically confirmed endometriosis/adenomyosis achieved better overall survival than those without, the benefit was linked to stage, grade, age, and histological subtype.

In a poster presentation from Society of Gynecologic Oncology 2022 Annual Meeting, investigators led by Cara Mathews, MD, aimed to determine the benefit of dostarlimab vs standard-of-care doxorubicin for advanced recurrent endometrial cancer.

Cara Mathews, MD, spoke with CancerNetwork® about research examining dostarlimab vs doxorubicin for patients with mismatch repair–deficient endometrial cancers.

Brian Slomovitz, MD, Reviews Adjuvant Pembrolizumab and Chemo +/– Radiotherapy in Endometrial Cancer

Pembrolizumab has been approved by the FDA for the use in advanced microsatellite instability–high/mismatch repair–deficient endometrial cancer following prior systemic therapy.

A survival benefit was observed in patients with advanced or recurrent endometrial cancer who were treated with maintenance selinexor.

The ongoing KEYNOTE-B21 trial aims to determine if pembrolizumab plus adjuvant chemotherapy with or without radiotherapy will improve disease-free survival and overall survival in patients with newly diagnosed endometrial cancer.

Results presented at an ESMO Virtual Plenary in March 2022 show that maintenance therapy with selinexor decreased the risk of progression or death for patients with advanced or recurrent endometrial cancer.

The KEYNOTE-775 trial found that lenvatinib plus pembrolizumab prolonged progression-free survival compared with chemotherapy for patients with endometrial cancer.

Topline findings from the phase 3 SIENDO trial did not appear to likely support a supplemental new drug application use of selinexor in patients with advanced or recurrent TP53 wild-type endometrial cancer, prompting the creation of a new phase 3 trial to support a future submission.

Patients with advanced endometrial cancer derived a more notable survival benefit after being treated with lenvatinib and pembrolizumab compared with chemotherapy alone.

The phase 3 SIENDO trial, examining the use of frontline maintenance selinexor after combination chemotherapy in patients with advanced or recurrent endometrial cancer, met its primary end point of a statistically significant improvement in progression-free survival.

Patients with microsatellite instability–high and mismatch repair–deficient advanced endometrial cancer experienced a long lasting benefit following treatment with pembrolizumab.

Patients with endometrial cancer who were treated with 30 Gy of 6 fractions of vaginal cuff brachytherapy presented with lower toxicity.

Investigators identified a link between high tumor mutational burden and high responses to dostarlimab among patients with endometrial cancer.

Phase 3 results demonstrating the superiority of the pembrolizumab plus lenvatinib combination vs standard chemotherapy served as a confirmatory trial for its approval in certain patients with advanced endometrial cancer.

Based on results from the phase 2 GARNET trial, dostarlimab may be used to treat recurrent or advanced endometrial cancer progressing on or after treatment with a platinum-containing chemotherapy that is mismatch repair deficient.

The androgen receptor inhibitor enzalutamide, an approved therapy for certain types of prostate cancer, has shown activity for the treatment of patients with recurrent or advanced endometrioid endometrial cancer.

The combination of cediranib and olaparib demonstrated modest efficacy in patients with recurrent, metastatic, or persistent endometrial cancer; however, this was not significantly different compared to cediranib alone.

Following a prior announcement that the phase 3 KEYNOTE-775 trial met both primary end points of progression-free and overall survival benefit, data for the pembrolizumab/lenvatinib combination were presented at the Society of Gynecologic Oncology 2021 Annual Meeting on Women’s Cancer.

“These findings suggest that similar to its benefits in ovarian cancer, NACT could potentially lower perioperative morbidity and may serve as an important treatment option among women with metastatic endometrial cancer,” the study authors wrote.

The pivotal phase 3 KEYNOTE-775/Study 309 trial evaluating the investigational use of pembrolizumab (Keytruda) plus lenvatinib (Lenvima) met its dual primary end points of overall and progression-free survival in patients with advanced endometrial cancer.

“Dostarlimab demonstrated durable antitumor activity in both dMMR and MMRp advanced and recurrent endometrial cancer,” said Ana Oaknin, MD, PhD.

The dual PI3K/mTOR inhibitor LY3023414 also displayed moderate single-agent activity in this study of patients with heavily pretreated advanced endometrial cancer.

Though physical activity guidelines are largely based on chronic diseases like cardiovascular disease and diabetes, these data suggest they are important to cancer prevention as well.

A research team from the Mayo clinic verified the known risk factors for endometrial cancer, while identifying a possible microbiome signature associated with the disease.

Patients with endometrial cancer pose a very high risk of dying from cardiovascular diseases in the year after diagnosis, suggesting the necessity of early involvement of cardiologists for these patients.

Endometrial cancer survival correlates with total number of chemotherapy cycles – but not whether they are started earlier than radiation, according to the results of a new study.

A recent Danish study showed pregnancy loss was not associated with later cancer development among women with various cancer types.